Annual report
2150.TEDINET S100VH00
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥10.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥9.3bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2020-01-01 → 2020-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.4bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥816m | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥14.1bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥14.2bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥13.1bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥10.7bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥2.7bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.3bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.5bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥10.0bn | at 2022-12-31d | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.1bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.4bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.7bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.2bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥431m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥303m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥332m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥288m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥260m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.4bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥47m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥25.79 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.9 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.7 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.11 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.64 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥256.96 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥252.23 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥224.11 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥183.42 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥74.02 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 79.0% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.4% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.6% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.8% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 10.2% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 20.4% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 28.7% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.2% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 400 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 345 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 277 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 161 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 124 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥7.5bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥7.5bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥8.2bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥2.1bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥2.2bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.7bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.2bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.2bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥1.5bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥1.6bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥926m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥13.2bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥13.0bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥12.3bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.5bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.0bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥2.0bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥11.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥9.8bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.2bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.8bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥32.78 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.98 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.04 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.5 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.29 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥12 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥6 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥6 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥258.82 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥247.11 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.94 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥183.84 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥77.15 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 84.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.7% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.3% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.0% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.3% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 26.4% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 34.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 46,872,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 46,872,000 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 46,872,000 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 46,872,000 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,048,000 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 201 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 182 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 173 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 147 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 120 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 53
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥24m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥10m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥10m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥13.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥1.7bn |
| Medical Degital Transformation Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥191m |
| Medical Degital Transformation Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥26m |
| Medical Degital Transformation Businessreportable segment | employees | at 2024-12-31 | 303 pure |
| Medical Degital Transformation Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥9.9bn |
| Medical Degital Transformation Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥9.9bn |
| Medical Degital Transformation Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Medical Degital Transformation Businessreportable segment | segment assets | at 2024-12-31 | ¥688m |
| Medical Degital Transformation Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥3.8bn |
| Medical Platform Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥34m |
| Medical Platform Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥7m |
| Medical Platform Businessreportable segment | employees | at 2024-12-31 | 50 pure |
| Medical Platform Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.3bn |
| Medical Platform Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.3bn |
| Medical Platform Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥1m |
| Medical Platform Businessreportable segment | segment assets | at 2024-12-31 | ¥56m |
| Medical Platform Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥274m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥225m |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥33m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥11.2bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥11.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥10m |
| —segment total | segment assets | at 2024-12-31 | ¥744m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥4.0bn |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥42m |
| Reconciling Itemsreconciling | depreciation | 2023-01-01 → 2023-12-31 | ¥58m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥14.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥1.8bn |
| Medical Degital Transformation Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥19m |
| Medical Degital Transformation Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥20m |
| Medical Degital Transformation Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥9.2bn |
| Medical Degital Transformation Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥9.2bn |
| Medical Degital Transformation Businessreportable segment | segment assets | at 2023-12-31 | ¥87m |
| Medical Degital Transformation Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥3.9bn |
| Medical Platform Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥298m |
| Medical Platform Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥607,000 |
| Medical Platform Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥1.1bn |
| Medical Platform Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥1.1bn |
| Medical Platform Businessreportable segment | segment assets | at 2023-12-31 | ¥985,000 |
| Medical Platform Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥264m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥317m |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥21m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥10.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥10.2bn |
| —segment total | segment assets | at 2023-12-31 | ¥88m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥4.2bn |
| Medical Degital Transformation Businessreportable segment | employees | at 2024-12-31 | 131 pure |
| Medical Platform Businessreportable segment | employees | at 2024-12-31 | 23 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,527
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)鈴木 泰司 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)藤井 淳一 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)医薬DX事業の売上高の期間帰属 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（セグメント情報等） | |
| Reference2 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項（連結財務諸表作成のための基本となる重要な事項） | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)鈴木 泰司 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)藤井 淳一 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)医薬DX事業の売上高の期間帰属 | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 5304372000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 8004016000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 9327876000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 10235856000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 11182987000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 1506676000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 2556965000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 2894309000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 2467035000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 2367971000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 815593000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 1609116000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 1847535000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1510623000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 1139848000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 987431000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 1477238000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 1820917000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1528166000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 1224927000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 3085357000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 8138635000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 10020043000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 11501516000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 11329679000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | 5319411000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |